trending Market Intelligence /marketintelligence/en/news-insights/trending/RIubxgFhbaYch4UOPM4Y8Q2 content esgSubNav
In This List

US FDA approves first generic versions of Lilly's ADHD drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves first generic versions of Lilly's ADHD drug

The U.S. Food and Drug Administration approved the first generic versions of Eli Lilly & Co.'s Strattera, a drug for the treatment of attention-deficit hyperactivity disorder in children and adults.

The generic atomoxetine will be marketed in multiple doses by Apotex Inc., Teva Pharmaceutical Industries Ltd.'s Teva Pharmaceuticals USA Inc., Aurobindo Pharma Ltd. and Glenmark Pharmaceuticals Ltd.

Eli Lilly reported Strattera sales of $854.7 million for the full year 2016.